Stock Events

Stock Events

Ideaya Biosciences 

$39.93
24
-$0.11-0.27% 08:49 Today

Statistics

Day High
40.07
Day Low
39.98
52W High
40.58
52W Low
23.23
Volume
23,845
Avg. Volume
-
Mkt Cap
3.86B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

10NovExpected
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Next
-1.22
-0.32
0.57
1.47
Expected EPS
-1.177806
Actual EPS
N/A

Financials

-51.99%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
218.71MRevenue
-113.7MNet Income

Analyst Ratings

50.57Average Price Target
The highest estimate is 60.00.
From 7 ratings within the last 6 months. This is not an investment recommendation.
Buy
86%
Hold
14%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow IDYA. It's not an investment recommendation.
NVIDIA
9
NVDA
Microsoft
8
MSFT
Amazon
8
AMZN
AMD
8
AMD

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Array Technologies
ARRY
Mkt Cap722.3M
Array BioPharma, acquired by Pfizer, specializes in the development of targeted cancer treatments, similar to Ideaya's focus.
Novartis
NVS
Mkt Cap301.95B
Novartis offers a wide range of cancer treatments, including targeted therapies that compete with Ideaya's product pipeline.
AMGEN
AMGN
Mkt Cap237.52B
Amgen has a strong focus on oncology and precision medicine, making it a direct competitor in the development of cancer treatments.
Merck
MRK
Mkt Cap376.37B
Merck's extensive portfolio in oncology, including targeted therapies and immunotherapies, places it in competition with Ideaya.
Bristol-Myers Squibb
BMY
Mkt Cap136.88B
Bristol Myers Squibb, with its range of cancer treatments and focus on innovative therapies, competes in the same space as Ideaya.
Gilead Sciences
GILD
Mkt Cap181.18B
Gilead Sciences, known for its work in antiviral drugs, has expanded into oncology, competing with Ideaya's cancer focus.
Pfizer
PFE
Mkt Cap159.99B
Pfizer's broad oncology portfolio, including targeted therapies, makes it a competitor in the cancer treatment market.
Agios Pharmaceuticals
AGIO
Mkt Cap1.98B
Agios Pharmaceuticals focuses on cellular metabolism and rare genetic diseases, including cancer, competing with Ideaya's targeted approach.

About

IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
Show more...
CEO
Yujiro S. Hata
Employees
145
Country
United States
ISIN
US45166A1025
WKN
000A2PJPB

Listings

STU
DE
30J.STU
MU
DE
30J.MU
F
DE
30J.F
XNAS
US
IDYA

0 Comments

Share your thoughts

FAQ

What is Ideaya Biosciences stock price today?▼
The current price of IDYA is $39.93 USD — it has decreased by -0.27% in the past 24 hours. Watch Ideaya Biosciences stock price performance more closely on the chart.
What is Ideaya Biosciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Ideaya Biosciences stocks are traded under the ticker IDYA.
Is Ideaya Biosciences stock price growing?▼
IDYA stock has risen by +5.56% compared to the previous week, the month change is a +13.11% rise, over the last year Ideaya Biosciences has showed a +62.04% increase.
What is Ideaya Biosciences market cap?▼
Today Ideaya Biosciences has the market capitalization of 3.86B
When is the next Ideaya Biosciences earnings date?▼
Ideaya Biosciences is going to release the next earnings report on November 10, 2026.
What were Ideaya Biosciences earnings last quarter?▼
IDYA earnings for the last quarter are -1.22 USD per share, whereas the estimation was -1.06 USD resulting in a -15.47% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Ideaya Biosciences revenue for the last year?▼
Ideaya Biosciences revenue for the last year amounts to 218.71M USD.
What is Ideaya Biosciences net income for the last year?▼
IDYA net income for the last year is -113.7M USD.
How many employees does Ideaya Biosciences have?▼
As of August 25, 2026, the company has 145 employees.
In which sector is Ideaya Biosciences located?▼
Ideaya Biosciences operates in the Health & Wellness sector.
When did Ideaya Biosciences complete a stock split?▼
Ideaya Biosciences has not had any recent stock splits.
Where is Ideaya Biosciences headquartered?▼
Ideaya Biosciences is headquartered in SOUTH SAN FRANCISCO, United States.